Summit Therapeutics Inc. — Sponsor Intelligence | 3 EU Trials

Filter these 3 trials by condition, phase, country and more.

3 Registered trials

1 Recruiting

2 Completed trials

11 Countries active

11 Unique IMPs

100% Results reported

Phase III

Oversight events:

1 serious breach 1 corrective measure across 1 trial

100%

2 of 2 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

Top indications

3 total

A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizu… Recruiting

2025-521587-35-00 Phase III 8 countries IVONESCIMAB
HARMONi-3 Ended

2024-513087-26-00 Phase III 9 countries CARBOPLATIN; IVONESCIMAB; PACLITAXEL; PACLITAXEL ALBUMIN-BOUND; PEMBROLIZUMAB; P…
Effect of study drug combined with chemotherapy in patients with locally advanced or metastatic lung cancer with mutated receptor responsibl… Ended

2023-504434-22-00 Phase III 3 countries CARBOPLATIN; IVONESCIMAB; PEMETREXED; PEMETREXED DISODIUM

Showing 1–3 of 3 trials